M&A Deal Summary

Spark Therapeutics Acquires Genable Technologies

On March 7, 2016, Spark Therapeutics acquired life science company Genable Technologies for 15M USD

Acquisition Highlights
  • This is Spark Therapeutics’ 1st transaction in the Life Science sector.
  • This is Spark Therapeutics’ largest (disclosed) transaction.
  • This is Spark Therapeutics’ 1st transaction in Ireland.

M&A Deal Summary
Date 2016-03-07
Target Genable Technologies
Sector Life Science
Buyer(s) Spark Therapeutics
Deal Type Add-on Acquisition
Deal Value 15M USD

Target

Genable Technologies

Dublin, Ireland
Genable Technologies Ltd. is a development stage gene therapy company.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Spark Therapeutics

Philadelphia, Pennsylvania, United States
Category Company
Founded 2013
Sector Life Science
Employees50
Revenue 65M USD (2018)
DESCRIPTION

Spark Therapeutics, Inc. is a gene therapy provider seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark Therapeutics was founded in 2013 and is based in Philadelphia, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Ireland) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal